The objective of this study is to evaluate the safety and efficacy as assessed by the
Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of
MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate
Alzheimer's disease.